Current Research: Tirzepatide belongs to a class of drugs known as GLP-1 receptor agonists, also referred to as incretin mimetics. 

Research suggests that it may increase insulin release, stimulating the release of insulin from pancreatic beta cells in a glucose-dependent manner, meaning that more insulin is released when blood sugar levels are high. Suppressed glucagon release: It also helps to lower inappropriately high glucagon secretion, another hormone involved in regulating blood sugar, and delayed gastric emptying, just like Liraglutide slows down the movement of food from the stomach to the intestines, which helps to slow down the absorption of glucose.

Craving control and weight loss: Liraglutide interacts with GLP-1 receptors in the brain regions associated with craving regulation, leading to a decrease in food intake. This, in turn, can lead to weight loss and a reduction in body fat mass.

Contact Us for Pricing